Symbiotec Pharmalab IPO Lists Flat on NSE
Symbiotec Pharmalab Limited made its stock market debut on Tuesday, September 1, 2026, with its shares listing flat at its issue price of ₹988 on the NSE. On the BSE, the shares debuted at ₹978.20 apiece, reflecting a 1% discount to its issue price.
The ₹1,757.00 crore public issue was open for subscription from August 24 to August 27, 2026, and witnessed robust investor interest, with the IPO being subscribed 71.26 times by the close of bidding.
Symbiotec Pharmalab IPO - Issue Details
- Issue Type: Book Built Issue (Fresh Issue + OFS)
- Total Issue Size: Up to ₹1,757.00 crore
- Fresh Issue: Up to ₹150.00 crore
- Offer for Sale (OFS): Up to ₹1,607.00 crore
- Face Value: ₹2 per equity share
- Price Band: ₹938 to ₹988 per share
- Lot Size: 15 shares
- Minimum Investment Amount (Retail Investor): ₹14,820 (15 shares at the upper price)
- Listing: BSE, NSE
- Book Running Lead Managers: JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, Nomura Financial Advisory and Securities (India) Private Limited
- Registrar: MUFG Intime India Private Limited
Symbiotec Pharmalab Mart IPO Overall Subscription Status
[August 27, 2026, 7:00 P.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
172.03X |
|
Non-Institutional Investors (NIIs) |
73.63x |
|
Retail Individual Investors (RIIs) |
12.96x |
|
Total |
71.26x |
About Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited is a research-driven pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), complex injectables, and biotechnology-based products. Incorporated in 2002, it is a leading global manufacturer of corticosteroid and steroidal hormone APIs, with a portfolio of over 60 APIs.
The company operates vertically integrated manufacturing facilities in Madhya Pradesh for API production, fermentation, and injectable manufacturing. It also provides contract development and manufacturing (CDMO) services to pharmaceutical and nutraceutical companies across regulated international markets.
Key Financial Highlights
|
Particulars |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
|
Revenue from operations |
869.15 |
751.55 |
716.25 |
|
EBITDA |
231.97 |
206.11 |
177.04 |
|
Profit After Tax (PAT) |
109.90 |
96.79 |
100.05 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here